Pilot of a Trial Enrollment Diversity Dashboard (TEDD)

August 22, 2025 updated by: Andrew Hantel, MD, Dana-Farber Cancer Institute

Feasibility Pilot of a Trial Enrollment Diversity Dashboard (TEDD)

The goal of this study is to test the feasibility of a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) to ensure participant diversity in acute leukemia trial enrollment.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

This study is about testing a tool called the Trial Enrollment Diversity Dashboard (TEDD) to see if it can help increase diversity in cancer clinical trials, specifically for leukemia. Clinical trials are important for developing new cancer treatments, but not all groups are equally represented in these trials. This can lead to treatments that may not work as well for everyone.

The TEDD tool is designed to give medical professionals feedback on how diverse their patient enrollments are clinical trials. By using this tool, medical professionals can see if they are enrolling a diverse group of patients and make changes if needed.

The study will involve a small group of medical professionals who treat leukemia patients. They will use the TEDD tool and provide feedback on its usability and effectiveness. Study procedures include completion of surveys and usage of the TEDD intervention dashboard.

It is expected that about 12 medical professionals will take part in this research study. Participation in this research study is expected to last about 14 months.

The National Cancer Institute is providing funding for this research study.

Study Type

Interventional

Enrollment (Estimated)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Dana-Farber Cancer Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria Medical Professionals:

  • Physician, nurse practitioner, or physician assistant

    -≥10% clinical effort (or one ½ day of clinic per week for those working <1 FTE)

  • Treats adult patients with leukemia or related diseases at the study sites
  • Ability to understand and willingness to provide informed consent
  • Age 18 or older

Inclusion Criteria Participant Population:

  • Age ≥18 years old
  • Diagnosis of leukemia, lymphoma, myeloma, or related diseases
  • Seen by a physician for this diagnosis at one of the study sites

Exclusion Criteria Medical Professionals:

-Listed member of the research team

Exclusion Criteria Participant Population:

-Participants without the diagnoses of interest listed above, participants not seen at the study sites.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TEDD Intervention

12 medical professional participants will complete the following:

  • Baseline survey.
  • Usage and access of the TEDD intervention over a 12-month period.
  • Follow up surveys at the end of each quarter.
Behavioral: Trial Enrollment Diversity Dashboard Behavioral
A data management and classification algorithm tool that provides personalized enrollment diversity performance data for clinician review and which aims to overcome race-ethnic disparities in Leukemia clinical trial participation. Data inputs and the Dashboard are within existing HIPAA-complaint electronic health records systems used at Dana-Farber Cancer Institute, and utilization data metrics are collected through the Tableau software supporting the intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
TEDD Utilization Rate
Time Frame: 12 months
Utilization will be measured as the proportion of quarters where a participant accessed the dashboard divided by the total number of study quarters. Based on 12 participants over 4 three-month quarters, there are a total of 48 person-quarters available for analysis.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Dana-Farber Cancer Institute

Collaborators

National Cancer Institute (NCI)
American Society of Clinical Oncology

Investigators

  • Principal Investigator: Andrew Hantel, MD, Dana-Farber Cancer Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

June 30, 2027

Study Registration Dates

First Submitted

January 22, 2025

First Submitted That Met QC Criteria

January 22, 2025

First Posted (Actual)

January 27, 2025

Study Record Updates

Last Update Posted (Estimated)

August 28, 2025

Last Update Submitted That Met QC Criteria

August 22, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 24-544
  • K08CA273043-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD Sharing Time Frame

Data can be shared no earlier than 1 year following the date of publication

IPD Sharing Access Criteria

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Leukemia

Clinical Trials on Trial Enrollment Diversity Dashboard Behavioral

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe